Leadership

David Buckley , Ph.D.

David Buckley is currently the Director of Research and Innovation at XenoTech, LLC. David received a B.Sc. degree in chemistry and biology from Baker University (Kansas, USA) in 2002 and received a Ph.D. degree in toxicology and pharmacology from the University of Kansas Medical Center (USA) in 2007. After completing his doctoral training in toxicology and drug metabolism, David joined XenoTech in 2007 as a member of the R&D team and currently serves as the head of our consulting group. David's research focuses mainly on hepatic drug metabolism with an emphasis on cytochrome P450 and human-based in vitro systems for the pre-clinical evaluation of metabolism-based drug interactions. David has published several peer-reviewed journal articles in the fields of drug metabolism and toxicology and is a member of several scientific societies, including ISSX.

Faraz Kazmi , Senior Scientist

 
Faraz Kazmi is currently a Senior Scientist in the Research and Innovation group at XenoTech. Faraz graduated with a B.Sc. degree in cell and molecular biology in 2003 and a M.Sc. in biology in 2006 at Concordia University (Montreal, Canada). He is currently pursuing a Ph.D. in Toxicology at the University of Kansas Medical Center (Kansas City, USA) under the direction of Dr. Andrew Parkinson and Dr. Gregory Reed. After joining XenoTech in 2006, Faraz served as a Study Director in the P450 inhibition group, supervising GLP-compliant studies for regulatory submissions. In 2008, Faraz became involved with XenoTech's consulting service and R&D teams. Faraz's main research interest focuses on the victim/perpetrator potential for new molecular entities, with a special emphasis on in vitro based test systems for P450 mediated drug-drug interactions. Faraz is the author of several peer-reviewed publications and numerous scientific abstracts.

Joanna Barbara , Ph.D.

Joanna Barbara is a Mass Spectrometry Specialist in the Department of Drug Metabolism and Analytical Chemistry. She specializes in metabolite characterization and biotransformation route determination for drugs in development.

Dr. Barbara earned her Ph.D. degree in Analytical Chemistry from the University of Florida in 2007 under the joint direction of Dr. David Powell and Dr. John Eyler. Her research focused on developing techniques in high-resolution mass spectrometry for noncovalent complex analysis. She subsequently joined XenoTech where she is responsible for preclinical metabolism research on drug candidates. Current research interests include the application of accurate mass spectrometry to xenobiotic metabolism studies with a focus on reactive metabolites and metabolism-dependent inhibitors of drug metabolizing enzymes with potential for drug-drug interactions. Her other major area of interest is the development and application of novel analytical technologies, particularly in the area of mass spectrometry, for pharmaceutical research.

 

Maciej Czerwinski , Ph.D.

Maciej Czerwinski is an Executive Research Consultant at XenoTech.

Dr. Czerwinski received an M.Sc. degree in animal husbandry from the Main School of Rural Economy, Warsaw, Poland, in 1981 and received a Ph.D. in pathology from the University of Maryland at Baltimore, in 1993.  After completing his postdoctoral training in School of Pharmacy at the University of Washington and Fred Hutchinson Cancer Center in Seattle, Dr. Czerwinski joined XenoTech in 1998.  At XenoTech he held positions of Principal Scientist and Director of Cell & Molecular Biology overseeing XenoTech's R&D, Enzyme Induction and Products departments.

Dr. Czerwinski's research focuses on in vitro hepatic functions related to drug safety. At XenoTech, Maciej's heart lies in improving business process through scientific innovation.

Greg Loewen , Drug Transport

Greg Loewen graduated with a B.S. in Chemistry from Montana Tech in 1995 and performed natural products research for several years before joining XenoTech in 2000. From 2000 to 2005, Greg served as a Research Scientist and Study Director for GLP-compliant reaction phenotyping studies. In 2005, Greg focused his efforts in the analytical sciences group overseeing the development, validation and utilization of LC/MS methods in support of CYP enzyme inhibition, CYP enzyme induction and reaction phenotyping studies. In 2007 Greg accepted his current position of Senior Scientist in the Drug Transporter Department at XenoTech, overseeing drug transport studies and working with SOLVO Biotechnology and Sekisui Medical to promote their unique products and services in North America. Greg is an author or coauthor on several scientific posters and research publications.